Immutep Ltd - Asset Resilience Ratio
Immutep Ltd (IMM) has an Asset Resilience Ratio of 50.67% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Immutep Ltd (IMM) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how Immutep Ltd's Asset Resilience Ratio has changed over time. See Immutep Ltd shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Immutep Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Immutep Ltd (IMM) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$17.26 Million | 10.99% |
| Short-term Investments | AU$62.28 Million | 39.68% |
| Total Liquid Assets | AU$79.54 Million | 50.67% |
Asset Resilience Insights
- Very High Liquidity: Immutep Ltd maintains exceptional liquid asset reserves at 50.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Immutep Ltd Industry Peers by Asset Resilience Ratio
Compare Immutep Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Immutep Ltd (2001–2025)
The table below shows the annual Asset Resilience Ratio data for Immutep Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 50.67% | AU$79.54 Million ≈ $56.28 Million |
AU$156.98 Million ≈ $111.08 Million |
+7.54pp |
| 2024-06-30 | 43.13% | AU$86.94 Million ≈ $61.52 Million |
AU$201.58 Million ≈ $142.63 Million |
+40.70pp |
| 2023-06-30 | 2.43% | AU$3.59 Million ≈ $2.54 Million |
AU$147.45 Million ≈ $104.33 Million |
+2.14pp |
| 2022-06-30 | 0.30% | AU$302.00K ≈ $213.68K |
AU$102.17 Million ≈ $72.29 Million |
-9.80pp |
| 2021-06-30 | 10.10% | AU$8.28 Million ≈ $5.86 Million |
AU$82.03 Million ≈ $58.04 Million |
-18.94pp |
| 2020-06-30 | 29.03% | AU$13.53 Million ≈ $9.57 Million |
AU$46.60 Million ≈ $32.97 Million |
-6.43pp |
| 2014-06-30 | 35.46% | AU$9.00 Million ≈ $6.37 Million |
AU$25.38 Million ≈ $17.96 Million |
+11.08pp |
| 2013-06-30 | 24.38% | AU$8.00 Million ≈ $5.66 Million |
AU$32.81 Million ≈ $23.22 Million |
-26.19pp |
| 2012-06-30 | 50.57% | AU$21.05 Million ≈ $14.89 Million |
AU$41.61 Million ≈ $29.44 Million |
+33.23pp |
| 2011-06-30 | 17.35% | AU$10.00 Million ≈ $7.08 Million |
AU$57.64 Million ≈ $40.78 Million |
-35.25pp |
| 2010-06-30 | 52.60% | AU$10.00 Million ≈ $7.08 Million |
AU$19.01 Million ≈ $13.45 Million |
+40.53pp |
| 2007-06-30 | 12.07% | AU$526.17K ≈ $372.30K |
AU$4.36 Million ≈ $3.08 Million |
-28.43pp |
| 2006-06-30 | 40.50% | AU$2.98 Million ≈ $2.11 Million |
AU$7.36 Million ≈ $5.21 Million |
-39.77pp |
| 2005-06-30 | 80.28% | AU$7.33 Million ≈ $5.19 Million |
AU$9.13 Million ≈ $6.46 Million |
+79.93pp |
| 2004-06-30 | 0.35% | AU$20.00K ≈ $14.15K |
AU$5.77 Million ≈ $4.08 Million |
-0.83pp |
| 2001-06-30 | 1.18% | AU$50.00K ≈ $35.38K |
AU$4.24 Million ≈ $3.00 Million |
-- |
About Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more